ClinicalTrialStartPulse: Phase 1, page 3 of 4
Records 201 to 350 of the 500 newest listed for this hub. Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2.
| Record | Phase | Conditions | Enrollment |
|---|---|---|---|
| Centre for Addiction and Mental Health | Phase 1 | Treatment Resistant Depression; Autism Spectrum Disorder | 18 |
| The Third Xiangya Hospital of Central South University | Phase 1 | Healthy Volunteers | 62 |
| University of Pennsylvania | Phase 1 | Non-Hodgkin Lymphoma; Chronic Lymphocytic Leukemia; Acute Lymphoblastic Leukemia; Richter's Transformation | 6 |
| Pfizer | Phase 1 | Healthy | 52 |
| Jiangsu vcare pharmaceutical technology co., LTD | Phase 1 | Alopecia Areata | 24 |
| Astellas Pharma Global Development, Inc. | Phase 1 | Prostate Cancer | 56 |
| Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 1 | Overweight/Obesity | 80 |
| Amphista Therapeutics Ltd | Phase 1 | Acute Myeloid Leukaemia; High Risk Myelodysplastic Syndrome | 54 |
| UroGen Pharma, Inc., a subsidiary of UroGen Pharma Ltd. | Phase 1 | Bladder (Urothelial, Transitional Cell) Cancer; NMIBC; Urothelial Carcinoma Bladder; Urothelial Carcinoma in Situ; Urothelial Carcinoma Recurrent; Urothelial Carcinoma of the Urinary Bladder | 30 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | Phase 1 | Rheumatoid Arthritis; Systemic Lupus Erythematosus; Systemic Sclerosis; Sjögren's Disease | 63 |
| Eli Lilly and Company | Phase 1 | Obesity; Overweight | 34 |
| QuantX Biosciences, Inc. | Phase 1 | Atopic Dermatitis | 84 |
| Sichuan Baili Pharmaceutical Co., Ltd. | Phase 1 | Head and Neck Tumors; Solid Tumors | 30 |
| Nuravax, Inc. | Phase 1 | Alzheimer Disease; Alzheimer Disease (AD); Preclinical Alzheimer's Disease | 24 |
| Fujian Shengdi Pharmaceutical Co., Ltd. | Phase 1 | Psoriasis Vulgaris | 40 |
| Anxo Pharmaceutical Co., Ltd. | Phase 1 | Schizophrenia | 48 |
| Peter MacCallum Cancer Centre, Australia | Phase 1 | Metastatic Castrate Resistant Prostate Cancer (mCRPC) | |
| Virginia Commonwealth University | Phase 1 | Acute Myeloid Leukemia | |
| City of Hope Medical Center | Phase 1 | Sickle Cell Disease | |
| Vanderbilt University Medical Center | Phase 1 | Autonomic Failure; Pure Autonomic Failure; Multiple System Atrophy; Parkinson Disease; Orthostatic Hypotension | 34 |
| iBio, Inc. | Phase 1 | Obesity & Overweight | 32 |
| Aktis Oncology, Inc. | Phase 1 | NSCLC; NSCLC (Advanced Non-small Cell Lung Cancer); ES-SCLC; Small Cell Lung Cancer Extensive Stage; B7H3; Prostate Cancer | 152 |
| Beijing Suncadia Pharmaceuticals Co., Ltd | Phase 1 | Alzheimer's Disease | 50 |
| Ono Pharmaceutical Co., Ltd. | Phase 1 | Colorectal Cancer | 40 |
| Bristol-Myers Squibb | Phase 1 | Healthy Volunteers | 50 |
| BeOne Medicines | Phase 1 | Diffuse Large B-Cell Lymphoma; B-cell Malignancies | 70 |
| Beijing Suncadia Pharmaceuticals Co., Ltd | Phase 1 | Obesity; Overweight | 76 |
| Eli Lilly and Company | Phase 1 | Amyotrophic Lateral Sclerosis; Cytochrome P-450 Enzyme System | 32 |
| Pfizer | Phase 1 | Healthy | 12 |
| AstraZeneca | Phase 1 | Kidney Failure | 10 |
| Pfizer | Phase 1 | Healthy Participant | 8 |
| BeOne Medicines | Phase 1 | Diffuse Large B-Cell Lymphoma; B-Cell Malignancies | 70 |
| Bayer | Phase 1 | Chronic Kidney Disease | 16 |
| Hangzhou Yirui Pharmaceutical Technology Co., Ltd | Phase 1 | Safety; Tolerability; Pharmacokinetic | 64 |
| BioGeneric Pharma | Phase 1 | Neutropenia (Low White Blood Cell Count) | 50 |
| ThIA Santé Mentale | Phase 1 | Depression Chronic; Depression and Quality of Life; Depression; Major Depressive Episode | 608 |
| LTZ Therapeutics, Inc. | Phase 1 | Colorectal Cancer; Advanced/Metastatic Solid Tumor; Solid Tumor (Phase I); EPCAM; Colon Cancer | 152 |
| InventisBio Co., Ltd | Phase 1 | Healthy Subjects | 60 |
| Shandong Suncadia Medicine Co., Ltd. | Phase 1 | Breast Cancer | 18 |
| Shandong Boan Biotechnology Co., Ltd | Phase 1 | Solid Tumors | 120 |
| Chiesi Farmaceutici S.p.A. | Phase 1 | Idiopathic Pulmonary Fibrosis | 18 |
| Huahui Health | Phase 1 | Chronic HDV Infection | 88 |
| MEKanistic Therapeutics, Inc. | Phase 1 | Solid Tumors (Phase 1); HNSCC; Endometrial Cancer; Her2-negative Metastatic Breast Cancer; Pan-RAS and BRAF Wild-type Advanced; Metastatic Colorectal Cancer (CRC) | 71 |
| Chendu DIAO Pharmaceutical Group CO., LTD. | Phase 1 | Obesity, Overweight; T2DM (Type 2 Diabetes Mellitus) | 32 |
| Polaris Group | Phase 1 | Acute Myeloid Leukemia, Adult | 38 |
| Deciphera Pharmaceuticals, LLC | Phase 1 | Healthy Participants | 27 |
| AstraZeneca | Phase 1 | Healthy Participants | 19 |
| AeroRx Therapeutics Inc. | Phase 1 | COPD (Chronic Obstructive Pulmonary Disease) | 24 |
| AbbVie | Phase 1 | Healthy Volunteer | 36 |
| Bristol-Myers Squibb | Phase 1 | Systemic Lupus Erythematosus; Sjögren's Disease; Rheumatoid Arthritis; Idiopathic Inflammatory Myopathies; Systemic Sclerosis; Lupus Nephritis | 60 |
| The United Bio-Technology (Hengqin) Co., Ltd. | Phase 1 | Overweight , Obesity | 40 |
| Eccogene | Phase 1 | Steatohepatitis, Nonalcoholic; Osteo Arthritis | 40 |
| Incyte Corporation | Phase 1 | Healthy Participants | 10 |
| Atridia Pty Ltd. | Phase 1 | Immunology | 18 |
| Hangzhou Huasai Biomedicine Co., Ltd. | Phase 1 | Advanced Melanoma | 5 |
| argenx | Phase 1 | Healthy Volunteer; Healthy Adult Participants | 32 |
| Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Phase 1 | Healthy Subjects | 6 |
| Merck Sharp & Dohme LLC | Phase 1 | Ovarian Neoplasms; Endometrial Neoplasms | 80 |
| Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics | Phase 1 | Hepatic Impairment | 36 |
| Novo Nordisk A/S | Phase 1 | Fatty Liver Disease | 29 |
| Apogee Therapeutics, Inc. | Phase 1 | Asthma | 31 |
| Pfizer | Phase 1 | Carcinoma, Pancreatic Ductal; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | 64 |
| AbbVie | Phase 1 | Healthy Volunteer | 52 |
| AbbVie | Phase 1 | Healthy Volunteer | 8 |
| GlaxoSmithKline | Phase 1 | Healthy Participants; Gastrointestinal Neoplasms | 30 |
| Equillium | Phase 1 | Ulcerative Colitis | 70 |
| Adjuvia Therapeutics, Inc. | Phase 1 | Friedreich Ataxia; Cardiomyopathies; Central Nervous System Diseases; Neuromuscular Diseases; Mitochondrial Diseases; Mitochondrial Dysfunction | 60 |
| Eli Lilly and Company | Phase 1 | Healthy | 16 |
| Eli Lilly and Company | Phase 1 | C-Reactive Protein | 96 |
| Incyte Corporation | Phase 1 | Healthy Participants | 24 |
| Merck Sharp & Dohme LLC | Phase 1 | Healthy | 15 |
| Altis Medicines, Inc | Phase 1 | Autoimmune Disease | 50 |
| Chimivac INC | Phase 1 | Prostate Cancer Metastatic Castration-Resistant | 24 |
| Hoffmann-La Roche | Phase 1 | MASH | 56 |
| Tectonic Operating Company, Inc. | Phase 1 | Hereditary Hemorrhagic Telangiectasia (HHT) | 20 |
| Merck Sharp & Dohme LLC | Phase 1 | Healthy | 18 |
| GlaxoSmithKline | Phase 1 | Healthy Participants; Gastrointestinal Neoplasms | 36 |
| Ono Pharmaceutical Co., Ltd. | Phase 1 | Unresectable Colorectal Cancer | 65 |
| Ono Pharmaceutical Co., Ltd. | Phase 1 | Metastatic Pancreatic Cancer | 32 |
| Shanghai Qilu Pharmaceutical Research and Development Center LTD | Phase 1 | Healthy Participants Study | 70 |
| Acepodia Biotech, Inc. | Phase 1 | Hepatocellular Carcinoma (HCC); Hepatocellular Carcinoma Metastatic; Hepatocellular Carcinoma Non-Resectable | 70 |
| Qilu Pharmaceutical Co., Ltd. | Phase 1 | Breast Cancer | 80 |
| GlaxoSmithKline | Phase 1 | Healthy Participants; Gastrointestinal Neoplasms | 40 |
| AstraZeneca | Phase 1 | Staphylococcus Aureus Bloodstream Infection | 18 |
| Amgen | Phase 1 | Cardiometabolic Disease | 82 |
| Eli Lilly and Company | Phase 1 | Healthy | 60 |
| Chendu DIAO Pharmaceutical Group CO., LTD. | Phase 1 | Healthy Adult Subjects | 10 |
| Shionogi | Phase 1 | Renal Impairment | 30 |
| AstraZeneca | Phase 1 | Healthy | 72 |
| BeOne Medicines | Phase 1 | Hepatic Impairment; Healthy Adult Participants | 12 |
| Incyte Corporation | Phase 1 | Renal Insufficiency; Kidney Diseases | 24 |
| AbelZeta Inc. | Phase 1 | Systemic Sclerosis (SSc); Systemic Sclerosis; Systemic Sclerosis (Scleroderma); Systemic Sclerosis - 2013 ACR/EULAR Classification Criteria; Systemic Sclerosis Pulmonary; Systemic Sclerosis With Lung Involvement | 12 |
| BeOne Medicines | Phase 1 | Hepatic Impairment; Healthy Adult Participants | 24 |
| Lumen Bioscience, Inc. | Phase 1 | Viral Infections | 36 |
| HK inno.N Corporation | Phase 1 | Healthy Adult Male | 34 |
| Bristol-Myers Squibb | Phase 1 | Healthy Volunteers | 10 |
| Chiesi Farmaceutici S.p.A. | Phase 1 | Asthma; Healthy Volunteers | 120 |
| Incyte Corporation | Phase 1 | Hepatic Insufficiency; Liver Diseases | 24 |
| Ipsen | Phase 1 | Low-grade Glioma | 6 |
| Hoffmann-La Roche | Phase 1 | Cancer-Neoplasms | 34 |
| Yuhan Corporation | Phase 1 | Healthy Subjects | 46 |
| Jemincare | Phase 1 | Pain After Surgery | 48 |
| Biora Therapeutics, Inc. | Phase 1 | Healthy Subjects | 30 |
| Merck Sharp & Dohme LLC | Phase 1 | Psoriasis; Healthy | 132 |
| SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany | Phase 1 | Neurofibromatosis Type 1-Associated Plexiform Neurofibromas | 6 |
| Novo Nordisk A/S | Phase 1 | Overweight; Obesity | 41 |
| AstraZeneca | Phase 1 | Advanced Solid Tumor; Metastatic Colorectal Carcinoma; Head and Neck Squamous Cell Carcinoma; Non-small Cell Lung Cancer; Pancreatic Ductal Adenocarcinoma; Gastric Cancer | 13 |
| Genentech, Inc. | Phase 1 | Melanoma | 65 |
| Novo Nordisk A/S | Phase 1 | Obesity; Overweight | 63 |
| Akeso | Phase 1 | Advanced Solid Tumors | 243 |
| Sinocelltech Ltd. | Phase 1 | Healthy Participants | 12 |
| Pfizer | Phase 1 | Overweight; Obesity; Healthy Adults | 16 |
| Novo Nordisk A/S | Phase 1 | Obesity; Overweight | 60 |
| AbbVie | Phase 1 | Non-Hodgkin's Lymphoma | 21 |
| Fujian Shengdi Pharmaceutical Co., Ltd. | Phase 1 | Overweight and Obesity | 48 |
| GlaxoSmithKline | Phase 1 | Pneumonia, Bacterial | 46 |
| Mirati Therapeutics Inc. | Phase 1 | Healthy Participants | 10 |
| Great Novel Therapeutics Biotech & Medicals Corporation | Phase 1 | Solid Tumor (Phase I); Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) | 70 |
| Fortvita Biologics (USA)Inc. | Phase 1 | Healthy Volunteers (HV) | 32 |
| Merck Sharp & Dohme LLC | Phase 1 | Healthy | 30 |
| Molecular Partners AG | Phase 1 | Leukemia; Myeloid; Acute; Newly Diagnosed | 80 |
| Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Phase 1 | Healthy | 196 |
| NovaGo Therapeutics AG | Phase 1 | Acute Spinal Cord Injury (SCI); Spinal Cord Diseases; Spinal Cord Injuries; Trauma Nervous System | 120 |
| Viking Therapeutics, Inc. | Phase 1 | Obese Adults | 270 |
| ModernaTX, Inc. | Phase 1 | Ebola-Bundibugyo Virus Disease (Ebola-BDBV) | 84 |
| Jiangsu Hansoh Pharmaceutical Co., Ltd. | Phase 1 | To Compare the Pharmacokinetic (PK) Differences of HS-10504 Between Participants With Hepatic Impairment and Participants With Normal Hepatic Function | 32 |
| Shanghai Argo Biopharmaceutical Co., Ltd. | Phase 1 | Healthy Participants Study | 24 |
| Innovent Biologics (Suzhou) Co. Ltd. | Phase 1 | Hypertension | 30 |
| AbbVie | Phase 1 | Healthy Volunteers | 40 |
| Thetis Pharmaceuticals LLC | Phase 1 | Ulcerative Colitis (UC) | 24 |
| Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Phase 1 | Solid Tumor | 208 |
| Guangzhou Patronus Biotech Co., Ltd. | Phase 1 | Malaria Vaccine | 72 |
| Novo Nordisk A/S | Phase 1 | Healthy Volunteers | 148 |
| Shandong Suncadia Medicine Co., Ltd. | Phase 1 | Cardiomyopathy | 58 |
| Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Phase 1 | Overweight and/or Obesity; Healthy Participants | 135 |
| Hunan Kelun Pharmaceutical Co., Ltd. | Phase 1 | Healthy Volunteers | 30 |
| Guangdong Raynovent Biotech Co., Ltd | Phase 1 | Basic Science | 68 |
| Loki Therapeutics, Inc. | Phase 1 | Pancreas Cancer, Duct Cell Adenocarcinoma; Pancreatic Cancer; Advanced Pancreatic Adenocarcinoma | 18 |
| AbbVie | Phase 1 | Healthy Volunteer | 12 |
| AstraZeneca | Phase 1 | Human Metapneumovirus Infection | 144 |
| Sunshine Lake Pharma Co., Ltd. | Phase 1 | Advanced Malignant Solid Tumors | 110 |
| Shanghai Minwei Biotechnology Co., Ltd | Phase 1 | Healthy Volunteers; Obesity | 48 |
| Juri Biosciences, Inc. | Phase 1 | Metastatic Castration Resistant Prostate Cancer; Oligometastatic Prostate Cancer (OMPC); Metastatic Hormone Sensitive Prostate Cancer | 210 |
| Guangdong Hengrui Pharmaceutical Co., Ltd | Phase 1 | Body Weight Management | 50 |
| Keymed Biosciences Co.Ltd | Phase 1 | Healthy | 40 |
| MacroGenics | Phase 1 | Urothelial Cancer; GastroEsophageal Cancer; Colorectal Cancer; Esophageal Cancer; Gastric Cancer (GC); Pancreatic Cancer | 314 |
| Attovia Therapeutics Inc | Phase 1 | Ulcerative Colitis (UC) | 96 |
| Teikoku Pharma USA, Inc. | Phase 1 | Healthy Subjects | 20 |
| Shanghai Lanyi Therapeutics Co., Ltd. | Phase 1 | Generalized Myasthenia Gravis (gMG) | 18 |
| ViiV Healthcare | Phase 1 | HIV Infections | 112 |
All ClinicalTrialStartPulse record reports